This week the conference cycle continues with the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) (Twitter #ASGCT20).
Due to the ongoing travel challenges and need for social distancing as result of Covid–19, one key annual immunology meeting originally slated for this month was AAI in Honolulu, which was sadly cancelled. Fortunately, ASGCT is being held as a live virtual meeting instead, so do check it out if you have a keen interest in this field.
One area we’re hoping to learn more about at ASGCT20 is cell therapy using natural killer (NK) cells. It’s an exciting and emerging area, which is attracting a lot of interest of late.
Those following the NK cell space will no doubt have seen the recent announcement of the collaboration between Kite/Gilead and Melbourne based oNKo-innate, co-founded by Prof Nick Huntington (@Dr_Nick_Bikes) and Dr Jai Rautella (Link to PR).
Other NK focused companies in the news include the licensing by Avectas of the CAR-NK cell therapy from Galway based ONK Therapeutics, founded by Prof Mike O’Dwyer (@MichaelodwyerMD) (Link to PR).
It’s definitely an exciting time to be an NK cell biologist!
In our ongoing series of expert interviews, we caught up with Prof Huntington from Melbourne to talk about the potential of CAR-NK cell therapies.
To learn more from our oncology analysis and get a heads up on insights and commentary emerging in the NK cell niche, including our latest expert interview subscribers can log-in or you can click to gain access to BSB Premium Content.
Yesterday we looked at ten innovative approaches centred around T cell-based developments emerging from the American Society of Hematology (ASH) meeting that is taking place in Orlando next month.
Let’s not forget, however, that there are also other immune cells, including NK cells and quite a few others, which can be manipulated into cancer therapeutics for the treatment of hematologic malignancies.
Some of these are intriguing early preclinical research that may form next generation technologies in the future, while others take the form of up and coming early clinical data that readers may be interested to learn more about.
Here we highlight nine emerging immunotherapy approaches to consider that don’t involve T cells…
Curious to find out more about these novel ideas or iterations and get a heads up on insights from our ASH19 commentary? Subscribers can log-in or you can click to gain access to BSB Premium Content.
Increasingly we are seeing more research on the inflammatory status of the tumour microenvironment (TME) in recent years, not to mention the impact of cytokine and chemokine signalling pathways, and how they can be manipulated therapeutically.
There’s also a much wider range of novel immunotherapy approaches being evaluated such as checkpoints, CARs and vaccines with respect to both T and NK cell therapies. There are also a few other immune cells being targeted for developmental therapeutics.
As part of the ongoing CICON18 Preview series, we take a look at what’s in store and why the latest ten we’ve highlighted matter in the broader context of the evolving landscape…
For those who missed it, Part 1 can be found here.
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.